This study demonstrate that both IgA and IgG antibodies against the SARS-CoV-2 RBD can be used to detect COVID-19 patients even at the acute phase with high specificities and sensitivities while IgM sensitivity levels against the RBD are lower. The gene discussed is CD79A; the disease is COVID-19.